



European Monitoring Centre
for Drugs and Drug Addiction



The elimination of viral hepatitis among people who inject drugs in the EU


Monitoring data from the EMCDDA

T. Seyler, F. Pericoli, for the DRID network - VHPB April 2023



Methods : the elimination barometer

Monitoring and evaluation framework: indicators to monitor and evaluate the health sector response to viral hepatitis B and C among people who inject drugs



Adapted from [Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework](#), World Health Organization (2016).

Methods


EMCDDA Reitox national focal points

- **DRID network**
 - Seroprevalence studies
 - Routine diagnostic tests in drug treatment services
 - *Ad-hoc* surveys among experts
- **PDU network**
 - Indirect statistical methods for denominators
- **HR network**
 - Programmatic data



Context and need: denominators

Hi wtg'30RYE'r qr wv'kq'uk g'cpf'r t'gxcngpeg'tcvgu.'4243'qt'ncvguv
 Ęxc'kdng'f'cw



O g'vj qf'q'h'guvlo cv'kq'

VO <Vtgc vo gpv'Ow'nr dgt=ET <Ecr wtg/tgecr wtg=VR <Vt'wpec vgf'Rq'kuuq=EO <Eqo d'p'gf'O g'vj qf u=J O <J K

Ow'nr dgt=O O <O q'tc'rk' {Ow'nr dgt=O KO <O w'nr t'lc v'g'f'f'lec v'q't'O g'vj qf'


Uq'wteg <CO EFFC

Imputation model: EU27+Norway PWID population size of 520,000 [375,000 – 722,000]



Context and need: HCV prevalence

Figure 4. Prevalence (%) of active HCV infection (HCV RNA+) among PWID, by country, 2021 or latest available data




Note: The level of evidence is assessed separately for sero-prevalence studies (SP) and routine diagnostic tests (DT on: PWID case definition, sample size, type of settings, number of sites, type of biological sample. SP are also assess sampling method; DT for: timeliness, periodicity, geographical coverage.

Source: EMCDDA

Context and need: HBV prevalence

Figure 5. Sero-prevalence studies: Prevalence (%) of active HBV infection (HBsAg+) among PWID, by country, 2021 or latest available data




Note: The level of evidence is assessed separately for sero-prevalence studies (SP) and routine diagnostic tests (DT) on: PWID case definition, sample size, type of settings, number of sites, type of biological sample. SP are also assessed sampling method; DT for: timeliness, periodicity, geographical coverage.

Source: EMCDDA


Prevention: opioid agonist treatment

Hi wtg"; 0Rtqr qtvkqp"qh'j ki j / tkun'qr kqkf "wugtu'p"qr kqkf "uwduvkwkqp"vtgcwo gpv.'Gwtqr gcp"eqwptkgu."4243
 qt'hevguv'exckndrg'f cvc




Prevention: needle and syringe provision

High weight of evidence for needle and syringe provision in the UK. The weight of evidence for needle and syringe provision in the UK is high.




Prevention: combined OAT/NSP coverage

Figure 8. Number of clean syringes distributed per PWID and proportion of high-risk opioid users in opioid substitution treatment, European countries, 2021 or latest available data



Continuum of care

Continuum of HCV care among PWID (ever-injectors, n=7504) receiving drug services in Greece, April 2022 (source: Greek Reitox Focal Point of the EMCDDA)




Source: OKANA, KETHEA, 18 ANO Drug Dependence Treatment Unit, IANOS Drug Treatment Unit, ARGO Open Therapeutic Unit

Impact: trends in HCV-RNA prevalence

Hi wtg'380Mgpfu'lp'J EXTPC'r tgcngpeg'w +co qpi 'RYE<tguwu
ltqo 'fki pqule'vguvu'cpf'ugtqr tgcngpeg'uwwf lgu'y kj 'pcvqpcrlqt'o wmk/
Ekv{'eqxgtci g.'4236/4243

WHO target

Reduction in HCV viraemic prevalence by 80% from baseline (in general population and PWID)



Conclusions

- **Below target in terms of data availability**
 - Update of the DRID protocol : models of monitoring from study designs from Germany, Greece, Sweden, Luxembourg
- **Below target in terms of coverage of intervention**
 - Update of the joint ECDC/EMCDDA joint guidance: A package of technical reports on evidence reviews, expert panel consultation, models of good practice



International Journal of Drug Policy
Volume 109, November 2022, 103872



Review

Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020)

Norah Palmateer ^{a, b, R, I}, Victoria Hamill ^{a, b}, Anne Bergstrom ^c, Harriet Bloomfield ^a, Lara Gordon ^d, Jack Stone ^d, Hannah Fraser ^d, Thomas Seyler ^e, Yuejiao Duan ^a, Richard Tran ^a, Kirsten Trayner ^{a, b}, Christopher Biggam ^{a, b}, Shanley Smith ^{a, b}, Peter Vickerman ^d, Matt Hickman ^d, Sharon Hutchinson ^{a, b}



International Journal of Drug Policy
Volume 102, April 2022, 103588



Review


Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation

Tanja Schwarz ^{a, R, I}, Ilonka Horváth ^a, Lydia Fenz ^a, Irene Schmutterer ^a, Ingrid Rosian-Schikuta ^a, Otilia Mårdh ^b

Conclusions

- Below target in terms of coverage of intervention

➤ Models of care in **drug services**



➤ Models of care in **prisons**

1. **Ocaña (ES)**: comprehensive harm reduction package provided to drug users
2. **Milan (IT)**: HAV and HBV vaccination for people in prison and prison staff
3. **Luxembourg (LU)**: test & treatment activities
4. **Berlin (DE)**: interventions addressing viral hepatitis for females in prison
5. **Montpellier (FR)**: guaranteeing continuity of HCV care and treatment after prison release



Acknowledgments

The national focal points and expert network on drug-related infectious diseases (DRID):

Irene Schmutterer, Els Plettinckx, Elena Damian, Jérôme Antoine, Georgi Shopov, Josipa-Lovorka Andreić, Lara Jezic, Ioanna Yiasemi, Evi Kyprianou, Barbora Orlíková, Mathilde Pihl Badse, Liis Lemsalu, Henrikki Brummer-Korvenkontio, Anna Ndiaye, Eric Janssen, Ruth Zimmerman, Anastasios Fotiou, Ioanna Siamou, Anna Peterfi, Gergely Csaba Horváth, Sean Millar, Barbara Suligoj, Maria Elena Tosti, Anda Kivite-Urtane, Viktorija Stifanoviciute, Lina Jurgelaitiene, Carole Devaux, Vic Arendt, Pierre Braquet, Carlo Olivari D' Emanuele, Esther Croes, Robert Neil Whittaker, Jasmina Burdzovic, Thomas Sandøy, Magdalena Rosińska, Karolina Zakrzewska, Domingos Duran, Viviana Manolache, Valentina Ștefan, Peter Koren, Zuzana Kamendy, Irena Klavs, Begoña Brime Beteta, Noelia Llorens, Josefine Lundberg Ederth, Marie Nordahl, Maria Axelsson, Seda Kesemen, Peyman Altan

Correlation - European Harm Reduction Network: Rafaela Rigoni

European Centre for Disease Prevention and Control: Erika Duffell, Lina Nerlander, Anastasia Pharris, Teymur Noori

World Health Organization Regional Office for Europe: Antons Mozalevskis, Nicole Seguy, Giorgi Kuchukhidze

European Monitoring Centre for Drugs and Drug Addiction: Iciar Indave, Anne Bergenström, Linda Montanari, Isabelle Giraudon, Katerina Skarupova, Luk Van Baelen, André Noor